6. Noted Points
History of Contact
Distribution of Rashes
Crops of Rashes in various phases
Systemic Symptoms subsided in 3-4 days
7. About the culprit Agent
Virus
NEUROTROPIC
human herpesvirus- Alpha Herpes Virus
virus is enveloped with double-stranded DNA
genomes
encode more than 70 proteins
8. What does it do....?
Varicella-zoster virus (VZV) causes primary, latent,
and recurrent infections.
The primary infection is manifested as varicella
(chickenpox)
Recurrent infection known as Herpes zoster / Shingles
9. Interesting Data
USA –
Annual Case – 40 Lakh ,
Hospitalizations – 11000-15000
Deaths- 100-150
Primary Varicella – Mortality Rate- 2-3/ 100000 cases
Lowest among 1-9 yrs of age
Infants – 4 times risk
Adults – 25 times risk of dying
Mortality rate is 7-14% in untreated primary infection in immunocompromised
children
50 % in untreated adults with pneumonia
transmission of VZV to susceptible individuals occurs at a rate of 65-86%
contagious 24-48 hr before the rash is evident and until vesicles are crusted
2 Days before to 7 days/ crusting
13. Virus is transported in a retrograde manner through
sensory axons
dorsal root ganglia throughout the spinal cord
virus establishes latent infection in the neurons and satellite
cells
Subsequent reactivation of latent virus
herpes zoster
15. Varicella (Chickenpox)
Acute Febrile Rash
incubation period is 10 -21 days.
Subclinical varicella is rare
Prodromal symptoms
Fever
malaise
anorexia
headache
mild abdominal pain
Systemic Symptoms resolves within 2-4 days after onset of
rash
16.
17. Varicella lesions
appear first on the scalp, face, or trunk.
Centripetal Distribution
The initial exanthem consists of intensely pruritic
erythematous macules
papular stage
fluid-filled vesicles.
Clouding and umbilication of the lesions begin in 24-48 hr.
18. • simultaneous presence of lesions in various
stages of evolution is characteristic of varicella
• The number of varicella lesions 10 to 1,500
• Ulcerative lesions involving the mucosa of
oropharynx and vagina
19. vesicular lesions on the eyelids and
conjunctivae and mucosa
The exanthem may be much more
extensive in children with skin disorders
Hypopigmentation or hyperpigmentation
of lesion sites persists for days to weeks.
No Scarring or marks
20.
21.
22.
23. differential diagnosis
vesicular rashes caused by other infectious agents :-
enterovirus
monkey pox
rickettsial pox
S. aureus
drug reactions
disseminated herpes zoster
contact dermatitis
insect bites
Small Pox
24. Herpes zoster
reactivation of latent VZV.
uncommon in childhood
Zoster is not caused by exposure to a patient with varicella
The lifetime risk for herpes zoster for individuals with a
history of varicella is 10-20%
75% of cases occurring after 45 yr of age.
Herpes zoster is very rare in healthy children <10 yr of
age
2nd episode of HZ 4%
3 or more episodes are rare
Is Herpes Zoster Infectious ......???
25. vesicular rash that usually is dermatomal in
distribution.
necrotic changes may be produced in the
associated ganglia.
The skin lesions of varicella and herpes
zoster have identical histopathology
infectious VZV is present in both.
26. manifests as vesicular lesions clustered within 1 or 2
adjacent dermatomes
rash is mild, with new lesions appearing for a few days
Herpes zoster in children tends to be milder than
disease in adults
It occurs more frequently & disease is more severe if-
Children is on immunosuppressive therapy
HIV infected children.
postherpetic neuralgia is very unusual in children.
Transverse myelitis with transient paralysis is a rare
complication of herpes zoster
29. Varicella in Vaccinated Individuals
(“Breakthrough Varicella”)
One dose of varicella vaccine is >97% effective in
preventing severe varicella
85% effective in preventing all disease after exposure
to wild-type VZV.
Breakthrough disease is varicella that occurs in a
person vaccinated >42 days before rash onset and is
caused by wild-type VZV
30. rash occurring < 14 days after vaccination was most
commonly wild-type VZV
Rash occurring 14-42 days after vaccination was due
to either
Wild-type VZV-------- breakthrough varicella
vaccine strains---------vaccine-associated rash
????????
31. The Breakthrough varicella rashes are
atypical
predominantly maculopapular
vesicles are seen less commonly
illness is most commonly mild with <50 lesions
shorter duration of rash
Less contagious
Complications are less
little or no fever
32.
33. Progressive Varicella
Progressive varicella, is a severe complication of
primary VZV infection.
visceral organ involvement
coagulopathy
severe hemorrhage
Continued new vesicular lesion development
Severe abdominal pain
34. appearance of hemorrhagic vesicles
the risk for progressive varicella
congenital cellular immune deficiency disorders
Malignancy
organ transplantation
Pt. is on steroid therapy
Unusual clinical findings
develop a unique hyperkeratotic appearance
continued new lesion formation for weeks or months
35. Neonatal Varicella
Infants whose mothers demonstrate varicella in the period
from 5 days prior to delivery to 2 days afterward are at
high risk for severe varicella.
The infant acquires the infection transplacentally
The infant's rash usually occurs toward the end of the 1st
week to the early part of the 2nd week of life
maternal immunoglobulin G (IgG) is able to cross the
placenta if delivery occurs after 30 wk of gestation
?????
36.
37. Newborns whose mothers demonstrate varicella 5 days
before to 2 days after delivery should receive 1 vial of
VariZIG as soon as possible.
All premature infants born <28 wk gestation to a mother
with active varicella at delivery (even if the maternal rash
has been present for >1 wk) should receive VariZIG
intravenous immune globulin (IGIV) may provide some
protection
the infant should be treated with acyclovir (10 mg/kg every
8 hr IV) when lesions develop.
prognosis is good if pt. receive prompt antiviral therapy
38. Congenital Varicella Syndrome
In Utero Transmission
Risk of infection (No disease)
Early part of pregnency- 25%
Risk of CVS ( Disease)
Before 13 wks of gestation – 0.4%
In between 13 – 20 wks - 2%
39. CVS Manifestations
Organ/ System Manifestations
Skin Cicatricial skin scarring
LIMB Limb hypoplasia
NEUROLOGIC Microcephaly, cortical atrophy, seizures, and mental
retardation
EYE Chorioretinitis, microphthalmia, and cataracts
RENAL Hydroureter and hydronephrosis
ANS Neurogenic bladder, swallowing dysfunction, and
aspiration pneumonia
40.
41.
42.
43.
44. Diagnosis of CVS Fetopathy
The diagnosis of VZV fetopathy is based mainly on the
history of gestational varicella
presence of characteristic abnormalities in the newborn
infant
viral DNA may be detected in tissue samples by PCR.
VZV-specific IgM antibody is detectable in the cord
blood
Chorionic villous sampling
45. Diagnosis of varicella
Laboratory evaluation has not been considered
necessary
Leukopenia
relative and absolute lymphocytosis.
liver function tests are mildly elevated
CSF in CNS complications
mild lymphocytic pleocytosis
moderate increase in protein content
46. Rapid laboratory diagnosis
direct fluorescence assay
rapid culture with specific immunofluorescence staining
PCR amplification testing
multinucleated giant cells can be detected with
nonspecific stains Tzanck smear
VZV IgG antibodies:- Rise > 4 fold ???
Testing for VZV IgM antibodies is not useful
47. Treatment in Varicella
Acyclovir therapy is
Not Recommended Routinely
for treatment of
uncomplicated varicella in the otherwise
healthy child
the marginal benefit
the cost of the drug
low risk for complications of varicella.
48. Oral Acyclovir Theraphy
Oral acyclovir in
children >12 mo of age with
chronic cutaneous or pulmonary disorders
Pt. Is on corticosteroid therapy
individuals receiving long-term salicylate therapy
Possibly Secondary cases among household contacts ??
Nonpregnant individuals > 13 years of age
Dose – 20mg/Kg/ Dose QID for 5 days
Within 24 Hours of onset of exenthem
49. Intravenous Acyclovir therapy
Varicella with severe disease/ complicated cases
pneumonia
severe hepatitis
thrombocytopenia
encephalitis
varicella in immunocompromised patients
Dose:- IV acyclovir (10 mg/Kg/ Dose or 500 mg/m2 every 8 hr
IV) continued for 7–10 days
To be given even after > 72 Hours of Rash onset
Other molecules
famciclovir
Valacyclovir
Acyclovir-resistant VZV:- intravenous foscarnet
( 120 mg/kg/day TDS for upto 3 Wks)
50. Treatment in Herpes Zoster
uncomplicated HZ in children - antiviral agent may not always be necessary
herpes zoster in immunocompromised
Acyclovir (500 mg/m2 or 10 mg/kg every 8 hr IV).
Adults-
Acyclovir 800 mg 5 times a day for 5 days
Famciclovir 500 mg TDS for 7 days
Valacyclovir 1000 mg TDS for 7 days
Use of corticosteroids in the treatment of herpes zoster in children is not
recommended but can be given in elderly to improve quality of life.
51. Complications
more common in immunocompromised patients
In healthy child, mild varicella hepatitis is relatively
common
Mild thrombocytopenia occurs in 1-2%
Other Complications
Bacterial Infections
Encephalitis and Cerebellar Ataxia
Pneumonia
Nephritis and Nephrotic Syndrome
HUS
Arthritis
Mycocarditis
Pericarditiis
Pancreatitis and Orchitis
52. Bacterial Infections
Secondary bacterial infections of the skin
group A streptococci and S. aureus
occur in up to 5% of children
impetigo
cellulitis
lymphadenitis
subcutaneous abscesses.
manifestation of secondary bacterial infection
erythema of the base of a new vesicle.
Recrudescence of fever 3-4 days after the initial exanthem
54. Encephalitis and Cerebellar Ataxia
morbidity from CNS complications is highest among
patients < 5 yr
Nuchal rigidity
altered consciousness
seizures
gait disturbance
nystagmus, and slurred speech
Neurologic symptoms usually begin 2-6 days after the
onset of the rash.
Clinical recovery is rapid and is usually complete in
24-72 hrs
56. EVIDENCE OF IMMUNITY TO
VARICELLA
Evidence of immunity to varicella consists of any of the
following:
Documentation of age-appropriate vaccination with a
varicella vaccine:
• Preschool-aged children (i.e., aged >12 mo): 1 dose
• School-aged children, adolescents, and adults: 2 doses
Lab evidence of immunity or laboratory confirmation of
disease
Diagnosis or verification of a history of varicella disease/
herpes zoster by a health-care provider
57. Post exposure Prophylaxis
Vaccine:- given to healthy children within 3-5 days after exposure (
ASAP)
High-titer anti-VZV immune globulin is recommended
- immunocompromised children
- pregnant women without evidence of immunity
- newborns exposed to varicella
- Close contact b/w susceptible high risk patient and patient of HZ
- 1 vial / 125 Units .....per 10 Kg
- Max 625 Units
New Borns :
< 28 wks gestation, exposed to varicella, regardless of maternal
immunity
>28 wks gestation, exposed to varicella, no evidence of maternal
immunity
Adults – IG G titre to be done before anti VZV IG
58. Take Home Msgs
Identification of Disease
Laboratory Investigations
Treatment and Supportive t/t
Early identification of complications and management
Post exposure prophylaxis counselling
Syp Acyclovir 400mg/ 5ml , Zovirex 200 Rs
Tab Acyclovir 200 400 600 800 (146/ 5 Tab)
Inj Acyclovir , 250 mg , 246 Rs
Vaccine Rs 1700
VZV is a neurotropic human herpesvirus with similarities to herpes simplex virus, which is also α-herpesvirus. These viruses are enveloped with double-stranded DNA genomes that encode more than 70 proteins, including proteins that are targets of cellular and humoral immunity
Varicella-zoster virus (VZV) causes primary, latent, and recurrent infections. The primary infection is manifested as varicella (chickenpox) and results in establishment of a lifelong latent infection of sensory ganglion neurons. Reactivation of the latent infection causes herpes zoster (shingles).
morbidity and mortality in immunocompetent infants, adolescents, adults, as well as in immunocompromised persons; it predisposes to severe group A streptococcus and Staphylococcus aureus infections
contagious 24-48 hr before the rash is evident and until vesicles are crusted, usually 3-7 days after onset of rash. Susceptible persons may also acquire varicella after close, direct contact with adults or children who have herpes zoster
# By 2005, vaccination coverage had increased to 90% and varicella cases had declined 90-91% from those in 1995 in sites where active surveillance was being conducted. By 2002, varicella-related hospitalizations had declined 88% from 1994 and 1995.
# Subclinical varicella is rare; almost all exposed, susceptible persons experience a rash
# Prodromal symptoms may be present, particularly in older children and adults
#Temperature elevation is usually moderate, usually 100-102?F, but may be as high as 106?F; fever and other systemic symptoms usually resolve within 2-4 days after the onset of the rash.
While the initial lesions are crusting, new crops form on the trunk and then the extremities
# many children have vesicular lesions on the eyelids and conjunctivae, but corneal involvement and serious ocular disease are rare
# The exanthem may be much more extensive in children with skin disorders, such as eczema or recent sunburn.
# Hypopigmentation or hyperpigmentation of lesion sites persists for days to weeks in some children, but severe scarring is unusual unless the lesions were secondarily infected.
# Zoster is not caused by exposure to a patient with varicella; exposures to varicella boost the cell-mediated immune response to VZV in individuals with prior infection, decreasing the likelihood of reactivation of latent virus.
# Herpes zoster is very rare in healthy children <10 yr of age, with the exception of infants who were infected in utero or in the 1st year of life, who have an increased risk for development of zoster in the first years of life. Herpes zoster in children tends to be milder than disease in adults and is less frequently associated with postherpetic neuralgia
# In the elderly, herpes zoster typically begins with burning pain followed by clusters of skin lesions in a dermatomal pattern. Almost half of the elderly with herpes zoster experience complications; the most frequent complication is postherpetic neuralgia, a painful condition that affects the nerves despite resolution of the shingles skin lesions.
# Approximately 4% of patients suffer a 2nd episode of herpes zoster; 3 or more episodes are rare.
# . An increased risk for herpes zoster early in childhood has been described in children who acquire infection with VZV in utero or in the 1st year of life
rash occurring within the 1st 2 weeks after vaccination was most commonly wild-type VZV, reflecting exposure to varicella before vaccination could provide protection
# approximately 25-30% of breakthrough cases are not mild, with clinical features more similar to those of wild-type infection.
# contagiousness varies proportionally with the number of lesions: typical breakthrough cases (<50 lesions) are about a third as contagious as unvaccinated cases, whereas breakthrough cases with ≥50 lesions are as contagious as wild-type cases
illness is most commonly mild with <50 lesions
approximately 25-30% of breakthrough cases are not mild
Severe abdominal pain, which may reflect involvement of mesenteric lymph nodes or the liver
# appearance of hemorrhagic vesicles in otherwise healthy adolescents and adults, immunocompromised children, pregnant women, and newborns, may herald severe disease
@ malignancy, particularly if chemotherapy was given during the incubation period and the absolute lymphocyte count is <500 cells/mm3. The mortality rate for children who acquired varicella while undergoing treatment for malignancy and who were not treated with antiviral therapy approaches 7%; varicella-related deaths usually occur within 3 days after the diagnosis of varicella pneumonia
#@ High risk of progressive varicella
patients receiving high-dose corticosteroids
patients receiving inhaled corticosteroids
asthmatic persons receiving multiple short courses of systemic corticosteroid therapy
# Mortality is particularly high in neonates born to susceptible mothers who contracted varicella around the time of delivery.
# The infant acquires the infection transplacentally as a result of maternal viremia, which may occur up to 48 hr prior to onset of maternal rash
# The infant's rash usually occurs toward the end of the 1st week to the early part of the 2nd week of life (although it may be as soon as 2 days). Because the mother has not yet developed a significant antibody response, the infant receives a large dose of virus without the moderating effect of maternal anti-VZV antibody. If the mother demonstrates varicella >5 days prior to delivery, she still may pass virus to the soon-to-be-born child, but infection is attenuated because of transmission of maternal VZV-specific antibody across the placenta
@ Newborns whose mothers demonstrate varicella 5 days before to 2 days after delivery should receive 1 vial of VariZIG as soon as possible. Although neonatal varicella may occur in about half of these infants despite administration of VariZIG, it is usually mild
Fortunately, clinically apparent disease in the infant is uncommon
Most of the stigmata can be attributed to virus-induced injury to the nervous system, although there is no obvious explanation why certain regions of the body are preferentially infected during fetal VZV infection. The characteristic cutaneous lesion has been called a cicatrix, a zigzag scarring, in a dermatomal distribution
Chorionic villus sampling and fetal blood collection for the detection of viral DNA, virus, or antibody have been used in an attempt to diagnose fetal infection and embryopathy
@ Varicella immune globulin has often been administered to the susceptible mother exposed to varicella, but whether this step modifies infection in the fetus is uncertain. Similarly, acyclovir treatment may be given to the mother with severe varicella
@ Leukopenia is typical during the 1st 72 hours after onset of rash
# Laboratory evaluation has not been considered necessary for the diagnosis or management of healthy children with varicella or herpes zoster
# The atypical nature of breakthrough varicella, with a higher proportion of rashes being papular rather than vesicular, will pose diagnostic challenges
# Leukopenia is typical during the 1st 72 hours after onset of rash; it is followed by a relative and absolute lymphocytosis
#Rapid laboratory diagnosis of VZV is often important in high-risk patients and can be important for infection control
# VZV can be identified quickly by direct fluorescence assay (DFA) of cells from cutaneous lesions (vesicular fluid) in 15-20 min, by rapid culture with specific immunofluorescence staining (shell vial technique) in 48-72 hr, and by PCR amplification testing (vesicular fluid, crusts) in 2 hr to days
#VZV IgG antibodies can be detected by several methods, and a fourfold or greater rise in IgG antibodies is confirmatory of acute infection. VZV IgG antibody tests can also be valuable to determine the immune status of individuals whose clinical history of varicella is unknown or equivocal. Testing for VZV IgM antibodies is not useful for clinical diagnosis because commercially available methods are unreliable and the kinetics of the IgM response is not well defined
# The only antiviral drug available in liquid formulation that is licensed for pediatric use is acyclovir. Given the safety profile of acyclovir and its demonstrated efficacy in the treatment of varicella, treatment of all children, adolescents, and adults with varicella is acceptable
# acyclovir therapy is not recommended routinely by the American Academy of Pediatrics for treatment of uncomplicated varicella in the otherwise healthy child because of the marginal benefit, the cost of the drug, and the low risk for complications of varicella
Oral therapy with acyclovir (20 mg/kg/dose, maximum 800 mg/dose) given as 4 doses/day for 5 days can be used to treat uncomplicated varicella in: nonpregnant individuals >13 yr of age and children >12 mo of age with chronic cutaneous or pulmonary disorders, individuals receiving short-term, intermittent
# Acyclovir therapy does not interfere with the induction of VZV immunity
@ To be most effective, treatment should be initiated as early as possible, preferably within 24 hr of the onset of the exanthem. There is less clinical benefit if treatment is initiated more than 72 hr after onset of the exanthem
). Acyclovir has been used to treat varicella in pregnant women; its safety for the fetus has not been established
# Dose:- IV acyclovir (500 mg/m2 every 8 hr IV) therapy initiated within 72 hr of development of initial symptoms decreases the likelihood of progressive varicella and visceral dissemination in high-risk patients. Treatment is continued for 7–10 days or until no new lesions have appeared for 48 hr.
Antiviral drugs are effective for treatment of herpes zoster. In healthy adults, acyclovir (800 mg 5 times a day PO for 5 days), famciclovir (500 mg tid PO for 7 days), and valacyclovir (1,000 mg tid PO for 7 days) reduce the duration of the illness and the risk for development of postherpetic neuralgia; concomitant corticosteroid use improves the quality of life in the elderly. In otherwise healthy children, herpes zoster is a less severe disease, and postherpetic neuralgia is rare
# herpes zoster in immunocompromised children can be severe, and disseminated disease may be life threatening
In healthy child, mild varicella hepatitis is relatively common but rarely clinically symptomatic
# Mild thrombocytopenia occurs in 1-2% of children with varicella and may be associated with transient petechiae.
gait disturbance ,nystagmus, and slurred speech are the features of cerebellar ataxia
Varicella pneumonia is a severe complication that accounts for most of the increased morbidity and mortality in adults and other high-risk populations, but pneumonia may also complicate varicella in young children
Newborns whose mothers demonstrate varicella 5 days before to 2 days after delivery should receive 1 vial of VariZIG. VariZIG is also indicated for: pregnant women without evidence of immunity
premature infants born at <28 wks of gestation (or weight <1,000 g) who were exposed to varicella during the neonatal period, regardless of maternal immunity
premature infants born at >28 wks of gestation who were exposed to varicella and whose mothers have no evidence of varicella immunity